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Abstract
We examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to
members of the ErbB - ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells.
Under an androgen-reduced condition, 50 nM gemcitabine caused about 40% growth suppression
on C-81 cells. Simultaneous treatment of gemcitabine plus 10 µM AG825 produced 60% suppression
(p<0.03); while, 85% growth inhibition (p<0.02) was seen if AG825 was added to gemcitabinetreated cells after a 24 hr-interval. Our data thus showed that in androgen-reduced conditions,
inhibition of ErbB-2 increases the cytotoxic efficacy of gemcitabine in PCa cells. This finding has
significant implications in the choice of drugs for combination therapy as well as the order of
administration for treating cancer patients.
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1. Introduction
Prostate cancer (PCa) is the second leading cause of male cancer mortality in the United States
of America [1]. Several approaches, including surgery and radiation therapies, provide
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clinicians with effective options for treating patients with localized cancer; while androgen
ablation therapy remains the main choice for treating metastatic disease [2]. However, patients
with advanced PCa benefit only temporarily from androgen deprivation treatment, and the
disease progresses to hormone-refractory cancer [2]. Progress in treating this stage of PCa has
been very modest with only one chemotherapeutic agent – docetaxel - having demonstrated
any meaningful benefit. It is imperative to explore new therapeutic regimens with less toxicity
and higher efficacy.
Members of the ErbB family, including epidermal growth factor receptor (EGFR) and its
ligands and ErbB-2/HER-2/Neu, are frequently elevated and/or mutation-activated in a variety
of malignant diseases [3,4]. The activation of the mitogen-activated protein kinases (MAPKs)
can also contribute to tumorigenesis. In PCa, ErbB to MAPK signal pathway is activated,
correlating with hormone-refractory cancer progression [5–7]. The EGFR expression level is
suggested to be associated with Gleason scores as well as the androgen-independent stage, and
therefore the inhibition of EGFR signaling may suppress tumor angiogenesis [8]. ErbB-2
signaling also plays a critical role in PCa progression and correlates with hormone-refractory
proliferation [9,10]. These observations lead to the hypothesis that targeting the ErbB members
to MAPK signaling pathway could have therapeutic potential on those cancer cells. Thus,
developing inhibitors toward those molecules has been actively pursued for improving the
efficacy of cancer therapy.
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The members of the Bcl-2 family represent critical check points within apoptotic pathways.
Bcl-2 promotes cell survival by suppressing cellular apoptosis [11]. In PCa, up-regulation of
Bcl-2 correlates with its progression to the advanced hormone-refractory stage and increases
radiation resistance [11]. Conversely, pro-apoptotic Bax protein effectively antagonizes Bcl-2
action, thereby promoting apoptosis [12]. It appears that the ratio of anti-apoptotic proteins,
e.g., Bcl-2 and Bcl-XL, to pro-apoptotic proteins, e.g., Bax and Bad, determines at least in part
how cells will respond to apoptotic or survival signals [12]. To implement this approach in
practice is to shift the ratio to favor apoptosis by decreasing anti-apoptotic and/or increasing
pro-apoptotic gene expression [13].
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Combining different classes of drugs has proven effective in treating various cancers since the
drug resistance of cancers is likely due to the heterogeneity of cancer cell populations.
Nevertheless, drug combinations tend to be more toxic to normal cells and patients are more
susceptible to adverse side effects. A new strategy is thus critically needed. Inhibitors to protein
tyrosine kinases (PTKs), including ErbB family members, have been shown to enhance the
therapeutic efficacy of some conventional cytotoxic agents [7,14]. Combinations of MAP
kinase/ERK kinase (MEK) inhibitors with docetaxel can increase cellular apoptosis in
androgen-independent PCa cells under androgen-reduced conditions [7]. The same efficacy
on cell growth suppression could be achieved by the combination treatment with a lower dose
of cytotoxic agents plus inhibitors to signal transduction pathways, compared to combination
therapies with conventional drugs.
Cancer treatment with DNA-damaging agents is commonly used in clinic. Gemcitabine (2’,
2’-difluro-2’-deoxycytidine), an analog of deoxycytidine that inhibits DNA biosynthesis,
exhibits effective anticancer activity toward several cancers [15]. It is also considered to be
one of the most promising agents used in combination treatments [14,16]. Several clinical
studies have analyzed the efficacy of combined treatments of gemcitabine plus other agents
such as taxanes, vinorelbine, vindesine, cisplatin, 5-fluorouracil as well as anthracyclines
across various regimens and conditions of pretreatment [17–19]. Most of those two-drug
combination treatments have consistently demonstrated higher efficacy than either single
agent. Importantly, recent studies reveal a potential synergistic effect by combination
treatments with gemcitabine plus PTK inhibitors [20]. However, the efficacy of gemcitabine
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as a single agent or in combination utility for treating advanced PCa has yet to be fully
investigated [21].
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In this study, we investigated whether combination treatments could enhance the efficacy of
gemcitabine for treating hormone-refractory PCa, utilizing androgen-independent human PCa
LNCaP C-81 cells as the model system. These LNCaP C-81 cells exhibit many biochemical
features observed in clinical hormone-refractory PCa [22–24]. These cells thus serve as a useful
cell model in designing novel therapeutic approaches toward androgen receptor (AR) -positive,
androgen-independent PCa, the major population of advanced PCa cells. We investigated if
combination therapy of gemcitabine plus inhibitors to the ErbB signal pathway can reduce the
effective dose of gemcitabine, alleviating its impact on normal cells and concurrently
increasing its effect on growth suppression. To mimic clinical applications of chemotherapeutic
agents during androgen ablation therapy of PCa, we examined the combination efficacy on
suppressing LNCaP C-81 cells in an androgen-reduced condition.

2. Materials and methods
2.1. Materials
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Fetal bovine serum (FBS), cell culture medium RPMI 1640 and gentamicin were purchased
from Invitrogen Life Technologies (Carlsbad, CA). Specific antibodies (Abs) to Bcl-2 and Bax
and horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG Abs were from Santa
Cruz Biotechnology (Santa Cruz, CA). Charcoal/Dextran-treated, certified FBS was from
HyClone (Logan, UT). Docetaxel and gemcitabine were obtained from the Nebraska Health
System University Hospital. PD98059, AG825 and AG1478 were from Calbiochem (San
Diego, CA). All other reagents were obtained as described in previous publications [7,9].
2.2. Cell culture
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Human PCa cell line LNCaP was purchased from the American Type Culture Collection and
routinely maintained in the regular culture medium, i.e., phenol red (PR)-containing RPMI
1640 medium supplemented with 5% (v/v) FBS, 2mM glutamine and 50µg/ml gentamicin
[22,23]. LNCaP parental cells are androgen-sensitive and express prostate-specific antigen
(PSA). Upon passage, LNCaP cells gradually lost androgen sensitivity. For experiments,
LNCaP C-81 cells that had passage numbers between 80 and 120 and exhibited androgenindependent growth were used as the model system [22,23]. Despite the expression of
functional AR in LNCaP C-81 cells, the growth of C-81 cells is androgen-independent.
Furthermore, C-81 cells exhibit many biochemical characteristics as seen in advanced
hormone-refractory PCa, for example, in the presence of castrated levels of androgens, those
cells secrete PSA, exhibit rapid growth rates and high tumorigenecity in xenograft animals
[22–24]. Importantly, these cells exhibit intracrine regulation by biosynthesizing testosterone
from cholesterol as observed in some advanced PCa [25]. For determining cell growth, the
total cell number was counted using a Coulter Counter Z1 model [9].
2.3. Treatment with chemotherapeutic agents
For experiments, cells were seeded in the regular medium for 2 days and then fed with a steroidreduced (SR) medium, i.e., phenol-red (PR)-free RPMI 1640 medium containing 5% (v/v)
heat-inactivated, charcoal/dextran-stripped fetal bovine serum (CS-FBS), 2 mM glutamine and
50 µg/ml gentamicin. After 2 days, cells were fed with fresh SR medium and treated with
PD98059, AG825, AG1478, gemcitabine, or docetaxel, either alone or in combination, as
specified in each experiment, for 3 days [7]. To quantify the cell growth, attached cells were
trypsinized and cell number was counted with a Coulter Counter. All experiments were done
in triplicates and repeated at least twice.
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2.4. Western blotting
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Briefly, cells were scraped, pelleted and rinsed with ice-cold HEPES-buffered saline, pH 7.0,
and then lysed in an ice-cold cell lysis buffer containing a battery of protease and phosphatase
inhibitors [22,26]. For immunoblotting, the nitrocellulose membrane filter was blocked and
subsequently incubated with appropriate primary Ab. After rinsing, the filter was incubated
with secondary Ab. The protein bands were visualized by an ECL detection system. For
reblotting, filters were agitated with the stripping buffer for 30 min at 50°C [9,23].
2.5. TUNEL assay
A TUNEL assay Kit (Roche, Indianapolis, IN) was used to measure apoptosis [7]. Briefly,
cells were plated on coverslips in regular culture medium for 48 hr and then in SR medium for
an additional 48 hr. Cells were fed with fresh SR medium with or without reagents for 72 hr.
The apoptotic cells were detected by the commercial kit, following the accompanying protocol.
Apoptotic cells were observed under a light microscope and were counted in 5 randomly
selected fields.
2.6. Data analysis
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All western blot experiments were conducted at least twice and the most representative results
were presented. The intensities of hybridization bands were semi-quantified by densitometric
analyses of films with different exposure time periods, utilizing the BioRad Gel-Doc Gel
Imager [7]. The statistical procedures for p-value analysis were performed by the student t-test
with two populations to determine significance of comparisons. p<0.05 was considered as
significant difference.

3. Results
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We analyzed the growth suppression by combination treatments, utilizing cytotoxic agents plus
inhibitors to PTKs in clinic-relevant, androgen-independent human PCa LNCaP C-81 cells.
The utilization of C-81 cells is because these cells exhibit many biochemical properties as seen
in hormone-refractory PCa, e.g., in the absence of androgen, these cells secret PSA and exhibit
high tumorigenecity [22–24]. To mimic the clinical scenario in which androgen ablation is the
first line of treatment for patients with metastatic PCa, all experiments were conducted in a
steroid-reduced condition, in which phenol red-free medium was used because phenol red
exhibits stimulatory activity on androgen-sensitive LNCaP cells [27] Initial results showed
that both docetaxel and gemcitabine each inhibited the growth of LNCaP C-81 cells effectively,
following a dose-response manner (Fig. 1A). Clinic-relevant doses of gemcitabine at 50 nM
and of docetaxel at 2.4 nM alone inhibited the growth of C-81 cells by approximately 40% and
60%, respectively (Fig. 1A, upper panel). Furthermore, TUNEL assay analyses revealed that
growth inhibition on LNCaP C-81 cells by docetaxel and gemcitabine was at least in part due
to their effects on the apoptotic pathway (Fig. 1A, lower panel). We found that the limited
efficacy of growth suppression by these two cytotoxic agents was at least in part due to their
concurrent effects on increasing anti-apoptotic Bcl-2 and Bcl-XL protein levels (Fig. 1B).
We initially analyzed the efficacy of combination treatment with gemcitabine plus docetaxel.
Unexpectedly, the concurrent treatment of both cytotoxic agents did not enhance growth
inhibition. Only approximately 30% growth inhibition was observed with this combination,
lower than either agent alone (Fig. 2, lane #6 vs. #2 &3). Because several studies have shown
that the ErbB-2 – MAPK/ERK pathway is activated in PCa cells, especially in advanced
hormone-refractory cancer cells [7,9,28], we examined growth suppression on C-81 cells by
inhibitors to ErbB-2 and MEK, the up-stream of MAPK/ERK. Under androgen-reduced
conditions, at 10 µM concentration each, both ErbB-2 inhibitor AG825 and MEK inhibitor
PD098059 as single agents inhibited the growth of those cells only about 15% in a 3-day
Cancer Lett. Author manuscript; available in PMC 2010 November 18.
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treatment (Fig. 2, lane #4&5). Unexpectedly, PD098059 abolished the cytotoxic effect of
gemcitabine when both agents were administrated together (Fig. 2, lane #7). Nevertheless, the
combination of AG825 with gemcitabine exhibited an added effect with approximately 60%
growth suppression (p<0.03, lane #8 vs. #2). Interestingly, a synergistic effect with over 80%
growth suppression was obtained when AG825 was added to the culture 24h after their
exposure to gemcitabine (p<0.02, lane #9 vs. #2; p<0.05, #9 vs. #8). To rule out whether it is
a cell line-specific phenomenon, we tested the combined AG825 and gemcitabine treatment
on high passage MDA PCa2b cells, an AR-positive, androgen-independent PCa cells exhibiting
similar biochemical properties to C-81 cells and hormone-refractory PCa [29]. Our data clearly
showed that in the steroid-reduced condition, those cells also responded to the sequential,
combined treatment as observed on LNCaP C-81 cells (data not shown). Thus, in androgenreduced conditions, AG825, but not PD98059, can enhance the cytotoxic effect by gemcitabine
and a sequential combination treatment resulted in even greater growth suppression on ARpositive, androgen-independent PCa cells, representing the majority of hormone-refractory
PCa in clinic.
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To determine whether gemcitabine plus AG825 inhibited LNCaP C-81 cell growth by
enhancing the apoptotic pathway, we analyzed the expression of pro-apoptotic protein Bax and
anti-apoptotic proteins Bcl-2 and Bcl-XL in those treated cells. As shown in Fig. 3 (lane #2),
in 50 nM gemcitabine alone-treated C-81 cells, comparing with control cells (lane #1), Bax
protein level was elevated by approximately 5-fold, while the Bcl-XL was also elevated by
about 50% with only a minor increase of Bcl-2 protein level. Treatment with 2.4 nM docetaxel
alone (Fig. 3, lane #3) resulted in an elevated Bax protein level by about 2-fold with slight
elevation of Bcl-2 as well as Bcl-XL protein level. AG825 and PD98059, at 10 µM each, had
only moderate effects on both pro- and anti-apoptotic proteins (lanes #4&5). When combined
with gemcitabine, neither docetaxel (lane #6) nor PD98059 (lane #7) had a significant effect
on decreasing anti-apoptotic protein levels nor enhancing pro-apoptotic protein levels in treated
cells, comparing with gemcitabine alone-treated cells (Fig. 3, lane #2). Interestingly, when
AG825 was added to gemcitabine, Bcl-2 and Bcl-XL protein levels were decreased; lower than
that of gemcitabine alone-treated cells, with no significant change in Bax protein in those cells
(Fig. 3, lane #8 vs. #2). Additionally, when AG825 was introduced to the cell cultures 24-hr
after gemcitabine treatment, the Bax protein level was further elevated; while both Bcl-2 and
Bcl-XL protein levels were further decreased. These results therefore provide with a
mechanistic explanation that AG825-enhanced gemcitabine action on growth suppression in
those cells.
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We examined whether the inhibitor of EGFR could similarly enhance the susceptibility of C-81
cells to gemcitabine-induced apoptosis. C-81 cells were treated with the EGFR inhibitor
AG1478 plus gemcitabine, compared with AG825 plus gemcitabine in a steroid-reduced
condition. As shown in Fig. 4A, after a 72-hour treatment, 10 µM AG1478 exhibited
approximately a 15% growth suppression, similar to AG825 (lane #3 vs. #2). The combination
of 10 µM AG1478 plus 50 nM gemcitabine produced only approximately 30% growth
suppression (Fig. 4A, lane #6). In the same set of experiments, 50 nM gemcitabine plus 10 µM
AG825 achieved growth suppression by approximately 60% (Fig. 4A, lane #5). Thus, in a
steroid-reduced condition, inhibition of EGFR could not enhance the efficacy of gemcitabine
on C-81 cell growth suppression.
To elucidate further the molecular mechanisms of differential growth suppressions by
gemcitabine plus AG825 vs. AG1478 on C-81 cells, we examined their effects on the
expression levels of Bcl-2 and Bax proteins. In C-81 cells treated with either 50 nM gemcitabine
(lane #4), 10 µM AG1478 (lane #3) or AG825 (lane#2) alone, the level of anti-apoptotic Bcl-2
protein was elevated, higher than that in control cells (Fig. 4B). Furthermore, AG825 abolished
gemcitabine-induced increases of Bcl-2 protein level, resulting in expression levels even lower
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than in control cells (Fig. 4B, lane #5, Fig. 3, lane #8). Nevertheless, AG1478 enhanced
gemcitabine-induced Bcl-2 protein level in those cells, compared with that in single agenttreated cells (Fig. 4B, lane #6). Additionally, treatment of C-81 cells with gemcitabine or
AG825, but not AG1478, resulted in an elevated pro-apoptotic Bax protein level (Fig. 4B, lane
#2 & 4). The increase of Bax protein level was further enhanced by the combination treatment
of gemcitabine plus AG825, correlating with growth suppression (Fig. 4B, lane #5). Although
co-administration of AG1478 with gemcitabine could increase Bax protein level, in those cells,
anti-apoptotic proteins Bcl-2 (Fig. 4B, lane #6) and Bcl-XL (data not shown) were also greatly
elevated. The data collectively provided a mechanistic explanation for the lack of enhanced
efficacy of AG1478 in gemcitabine-induced apoptosis.

4. Discussion
The efficacy of chemotherapeutic regimens for treating advanced hormone-refractory PCa is
limited [2,30–32]. The objective of this study is to investigate whether the combination of
chemotherapeutic agents with PTK inhibitors can enhance the apoptotic pathway of androgenindependent human PCa cells in an androgen-reduced culture condition. We also elucidate the
mechanism of improved efficacy as it relates to changes in apoptotic proteins.
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We initially analyzed the effect of combination treatment of gemcitabine plus docetaxel. Each
agent alone exhibits efficacy toward several cancers, and their combination treatments have
shown promising results for treating advanced non-small cell lung cancer [33]. Our data
revealed that simultaneous administration of gemcitabine and docetaxel does not have an added
effect of growth suppression on androgen-independent PCa cells in an androgen-reduced
condition (Fig 2). Unexpectedly, the efficacy of growth suppression was decreased. We found
that adding docetaxel to gemcitabine decreases the amount of pro-apoptotic, Bax, compared
with gemcitabine alone and failed to decrease the amounts of the anti-apoptotic proteins, BclXL and Bcl-2 (Fig 3).
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We analyzed whether inhibitors to ErbB family members could add to the growth suppression
by gemcitabine, due to the importance of the ErbB family members in PCa progression [8,9,
34] and hormone-refractory proliferation [9,10,35–37]. We also investigated whether the MEK
inhibitor PD98059 could enhance gemcitabine efficacy because MAPK pathways are
associated with prostate cell mitogenesis and androgen-ablation survival [28], and also because
PD98059 can enhance docetaxel-induced apoptosis in androgen-independent PCa cells under
steroid-reduced conditions [7]. Interestingly, only AG825, but not PD98059 or AG1478, could
enhance the growth suppression induced by gemcitabine in AR-positive, androgenindependent PCa cells under a steroid-reduced condition. Our data thus support the notion that
ErbB-2, but not EGFR, plays a critical role in the androgen-independent proliferation of those
cells [9,22,35,36]. This observation that inhibition of EGFR activity in LNCaP C-81 cells does
not enhance growth inhibition by gemcitabine is in parallel with the observations that inhibition
of proliferation and induction of apoptosis is independent of EGFR activity in some other
cancer cells [38,39]. Additionally, this combined treatment in steroid-reduced conditions
should not have a profound effect on non-malignant prostate epithelia because they are
androgen-sensitive cells and will not proliferate under this environment even in the absence of
treatment.
Overexpression of Bcl-2 correlates with progression of a subgroup of PCa to the advanced
hormone-refractory stage [40,41]. Conversely, Bax effectively counteracts Bcl-2 function,
promoting cellular apoptosis. Therefore, alteration of their ratios for example by inhibition of
Bcl-2 and activation of Bax would lead to an apoptotic signal. We also analyzed the expression
level of Bcl-XL in those cells. Unexpectedly, blocking EGFR signaling does not enhance
gemcitabine-induced apoptosis of LNCaP C-81 cells despite the fact that Bax level is up-

Cancer Lett. Author manuscript; available in PMC 2010 November 18.

Zhang et al.

Page 7

NIH-PA Author Manuscript

regulated in those cells. The lack of enhancement of this combination treatment is at least in
part due to a concomitant elevation of both Bcl-2 and Bcl-XL protein levels (Fig. 4B, lane #6),
which compromises the Bax activity induced by gemcitabine. Conversely, AG825 can enhance
gemcitabine-induced growth suppression on androgen-independent LNCaP C-81 cells in a
steroid-reduced condition, which is at least in part due to the inhibition of Bcl-2 and Bcl-XL
and concurrently the elevation of Bax protein (Fig. 3). Our data reveal that combination
treatments could achieve growth suppression at lower concentrations than single agents alone
(Fig. 2, lane #8 vs. Fig. 1). Our data further suggest that the sequential administration of
gemcitabine and AG825 to patients could generate much more pronounced growth suppression
than simultaneous administration of both agents (Fig. 2, lane #9). For its potential clinical
applications, further studies in sequential dosing regimens of traditional anti-tumor agents and
signal transduction inhibitors are needed. Additionally, studies could also target the expression
of various apoptotic proteins to shift the ratio by enhancing pro-apoptotic over anti-apoptotic
proteins to favor cell death.
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Collectively, our data clearly show that ErbB-2 inhibition could enhance the gemcitabineinduced apoptosis, despite that several clinical evaluations show little advantage of either agent
in the monotherapy setting [32]. The data further highlight the important role of ErbB-2 protein
involvement in PCa progression, leading to hormone-refractory tumors. The results may then
serve as a platform for the future development of effective therapeutic approaches to advanced
PCa, particularly in the post-docetaxel patient for whom no standard-of-care exists. Further
studies should address whether gemcitabine plus ErbB-2 inhibitor together with hormonal
ablation therapy can delay the development of the androgen-independent phenotype and
improve patient survival.
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Fig. 1.

Chemosensitivity of LNCaP C-81 cells to gemcitabine or docetaxel in a steroid-reduced
condition. (A) Upper panel: LNCaP C-81 cells were cultured in androgen-reduced conditions
for 48 hrs and then were treated with docetaxel or gemcitabine alone for 72 hours. Cells were
harvested, and total cell number was counted. Bar represents SEs of triplicates in 2 sets of
independent experiments. Lower panel: TUNEL Assay for control cells treated with vehicle
alone (Control), cells treated with 50 nM gemcitabine (Gem) or 1.2 nM Docetaxel (Doc). (B)
An equal amount of total cell lysate proteins was separated by SDS-PAGE and transferred to
nitrocellulose membranes. The membranes were blotted with antibodies against of Bcl-2 or
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Bcl-XL. Hybridization with anti-ȕ-actin Ab was used as a loading control for each lane. Similar
results were obtained from at least 2 sets of independent experiments.
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Fig. 2.

Growth suppression of LNCaP C-81 cells by combination treatments of gemcitabine,
Docetaxel and ErbB-2 inhibitor in steroid-reduced conditions. C-81 cells in androgen-reduced
conditions were treated with gemcitabine (Gem, 50 nM), docetaxel (Doc, 2.4 nM), 10µM AG
825, 10µM PD98059 or different combinations as indicated in the figure for 3 days. Control
cells received solvent alone. Cell growth was measured by cell counting. The treatment in each
lane is as follows: lane 1- solvent alone; lane 2–50 nM gemcitabine alone; lane 3- 2.4 nM
docetaxel alone; lane 4– 10 µM AG825 alone; lane 5–10 µM PD98059 alone; lane 6Simultaneous treatment of 50 nM gemcitabine plus 2.4 nM docetaxel; lane 7- Simultaneous
treatment of 50 nM gemcitabine plus 10 µM PD98059; lane 8-Simultaneous treatment of 50
nM gemcitabine plus 10 µM AG825; lane 9–10 µM AG825 given 24h after treatment with
gemcitabine. Bars represent SEs of triplicates in 3 sets of independent experiments. *p<0.03,
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growth inhibition by 50 µM gemcitabine plus 10 µM AG825 vs. 50 µM gemcitabine alone;
**p<0.02, growth inhibition by 50 µM gemcitabine plus 10 µM AG825 in which AG825 was
added after 24 hours treatment with gemcitabine vs. 50 µM gemcitabine alone.
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Fig. 3.
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Molecular analyses on growth-suppressed LNCaP C-81 cells by combined treatments with
gemcitabine, docetaxel and ErbB-2 inhibitor. C-81 cells in androgen-reduced conditions were
treated with gemcitabine (Gem, 50 nM), docetaxel (Doc, 2.4 nM), 10 µM AG 825, 10 µM
PD98059 or different combinations as indicated in the figure for 3 days. Control cells received
solvent alone. The treatment in each lane is as follows: lane 1- solvent alone; lane 2–50 nM
gemcitabine alone; lane 3- 2.4 nM docetaxel alone; lane 4– 10 µM AG825 alone; lane 5–10
µM PD98059 alone; lane 6- Simultaneous treatment of 50 nM gemcitabine plus 2.4 nM
docetaxel; lane 7- Simultaneous treatment of 50 nM gemcitabine plus 10 µM PD98059; lane
8-Simultaneous treatment of 50 nM gemcitabine plus 10 µM AG825; lane 9–10 µM AG825
given 24h after treatment with gemcitabine. An aliquot of total cell lysates containing an equal
amount of proteins was separated by SDS-PAGE and then transferred to nitrocellulose
membranes. The membranes were blotted with antibodies against Bcl-2, Bcl-XL or Bax.
Hybridization of the same membrane with anti-ȕ-actin Ab was used as a loading control for
each lane. Similar results were obtained from at least 3 sets of independent experiments.
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Fig. 4.

Growth suppression of LNCaP C-81 cells by combination treatment of gemcitabine and ErbB
inhibitors. The C-81 cells in androgen-reduced conditions were treated with 50 nM gemcitabine
(Gem) in the presence or absence of 10 µM AG 825 or 10 µM AG1478 for 3 days. Control
cells received solvent alone. (A) Cell growth was determined by cell counting. Bars represent
SEs of triplicates in 2 sets of independent experiments. *p<0.03, growth inhibition by
gemcitabine plus 10 µM AG825 (lane #5) vs. gemcitabine alone (lane #4). (B) An equal amount
of total cell lysate proteins was separated by SDS-PAGE and transferred to nitrocellulose
membranes. The membranes were blotted with antibodies against of Bcl-2 or Bax.
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Hybridization of the same membrane with anti-ȕ-actin Ab was used as a loading control for
each lane. Similar results were obtained from at least 2 sets of independent experiments.
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